Sustained-release injectables formed in situ and their potential use for veterinary products

被引:59
作者
Matschke, C
Isele, U
van Hoogevest, P
Fahr, A
机构
[1] Novartis Anim Hlth Inc, CH-4002 Basel, Switzerland
[2] Phares Drug Delivery AG, CH-4132 Muttenz, Switzerland
[3] Univ Marburg, D-35037 Marburg, Germany
关键词
controlled release; sustained; injectable; in situ; implant; veterinary;
D O I
10.1016/S0168-3659(02)00266-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The controlled drug delivery of hydrophilic and lipophilic drug substances via the parenteral route has gained increasing importance in the development of pharmaceutical dosage forms. In particular, the animal health industry has generated strong interest in long-term drug delivery for both companion and farm animals during the past few years. At present sustained-release injectables formed in situ for s.c./i.m. administration have become an attractive alternative to common slow release technologies such as microspheres or standard implants. In this context, technologies based on PLA/PLGA, sucrose acetate isobutyrate (SAIB) and the amphipathic molecules Poloxamer, glycerol monooleate or PEG-PLA-PEG copolymers, are discussed. Release periods from hours to months can be obtained by choosing one of these drug delivery technologies. The release times are strongly dependent on the biodegradation of the polymers and the physico-chemical properties of the drug substance used. Furthermore, the use of different solvents for the matrix-forming agents and the individual loading capacity are critically assessed. Additionally acceptance of the excipients for parenteral use by the regulatory authorities is closely considered. Scientific articles as well as patent publications are reviewed to give a wide overview of the existing approaches and their future potential for animal health products. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 134 条
[1]  
[Anonymous], [No title captured], Patent No. [5, 252-318, 5252318]
[2]  
[Anonymous], [No title captured]
[3]   CONTROLLED-RELEASE NEW ANIMAL DRUGS [J].
ARNOLD, RG .
JOURNAL OF CONTROLLED RELEASE, 1988, 8 (01) :85-90
[4]   MICROSPHERES AND MICROCAPSULES, A SURVEY OF MANUFACTURING TECHNIQUES .3. SOLVENT EVAPORATION [J].
ARSHADY, R .
POLYMER ENGINEERING AND SCIENCE, 1990, 30 (15) :915-924
[5]   MICROSPHERES AND MICROCAPSULES, A SURVEY OF MANUFACTURING TECHNIQUES .2. COACERVATION [J].
ARSHADY, R .
POLYMER ENGINEERING AND SCIENCE, 1990, 30 (15) :905-914
[6]   HYDROGEL DELIVERY SYSTEMS BASED ON POLYMER BLENDS, BLOCK-COPOLYMERS OR INTERPENETRATING NETWORKS [J].
BAE, YH ;
KIM, SW .
ADVANCED DRUG DELIVERY REVIEWS, 1993, 11 (1-2) :109-135
[7]   Concentration of ofloxacin in canine prostate tissue and prostate: Fluid after intraprostatic injection of Biodegradable sustained-releasing microspheres containing ofloxacin [J].
Bahk, JY ;
Hyun, JS ;
Lee, JY ;
Kim, J ;
Cho, YH ;
Lee, JH ;
Park, JS ;
Kim, MO .
JOURNAL OF UROLOGY, 2000, 163 (05) :1560-1564
[8]  
Betschart R., 1998, P INT S CONTR REL BI, V25, P655
[9]   Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407 [J].
Bhardwaj, R ;
Blanchard, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (09) :915-919
[10]  
BLEIBERG B, 1993, AM J CLIN NUTR, V58, P908, DOI 10.1093/ajcn/58.6.908